Scientific achievements, especially in the field of pharmacology and drug development are numerous but include the design of the hollow fibre model of tuberculosis [“glass mouse”] for adult TB 2003.
Within the past year, he led the presentation for the formal qualification approval of the model as a drug development tool by the European Medicines Agency (EMA), the first of its kind: (https://goo.gl/iUZVuQ) and editorial endorsement by the US Food and Drug Administration [https://goo.gl/pGQDPJ]. This model has a predictive accuracy of 94% of clinical events, unprecedented in the field of pharmacology. Recently, he has added 3-D human organoids such as the liver to the model, leading to assessment of drug toxicity in the model.
Other scientific achievements include debunking the effectiveness of directly observed therapy in TB, introduction of the role of genetic pharmacokinetic variability as the main cause of therapy failure in TB, and recently overhauling the susceptibility breakpoints. He also pioneered PK/PD of anti-TB drugs and use of pharmaco-metrics in optimizing anti-TB drugs, and wrote the first systems pharmacology equations for interaction of drug and Mycobacterium tuberculosis (2004). He has also introduced the use of artificial intelligence algorithms to the TB field, and before that to infectious diseases while working on the antifungal micafungin. In the past, he designed the mouse model of disseminated Candida glabrata, and performed some of the PK/PD studies during development of all currently licensed echinocandin antifungals. In 2007, he received the NIH Director’s New Innovator Award. He has been the principal investigator for numerous research grants funded by the NIH, Critical Path, Gates, MRC-SA, and pharmaceutical industry grants. He has also been on the drug Safety Monitoring Committee, CROMS Safety Oversight Committee Support, DMID, NIH/NIAID. Dr Gumbo founded Jacaranda Biomed Inc., a company dedicated to helping pharmaceutical companies de-risk lead molecules, improve forecasting early during development for efficacy and toxicity based on innovative tissue platforms, dynamic drug concentrations, next-generation sequencing, and mathematical algorithms. Jacaranda Africa aims to provide a service for rapid evaluation of API for any products being sold on the African continent. He is also a founding partner of Yangu Beauty, a company that has created the first complete skin care line for women of colour (African, Asian, Caribbean, and Middle Eastern) and is the co-founder of Munhu Inc. a 501 (C) 3 in 2004. Munhu Inc. has cared for >20,000 AIDS Orphans in Zimbabwe since its founding. His education includes a Medical Degree (MB, ChB) from the University of Zimbabwe Medical School, Harare, Zimbabwe, Residency in Internal Medicine at Case Western Reserve University, Cleveland, Ohio, and Fellowship, in Infectious Diseases at the Cleveland Clinic, Cleveland, Ohio.